Results 61 to 70 of about 47,017 (70)

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

Journal of Clinical Oncology, 2005
Thomas E Witzig, Irene Ghobrial, David J Inwards   +2 more
exaly  

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

International Journal of Cancer, 2006
Ryuichiro Doi
exaly  

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Clinical Cancer Research, 2010
Allan B Dietz, Jan C Buckner
exaly  

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

Molecular Cancer Therapeutics, 2009
Cherie-Ann Nathan, Facs
exaly  

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

Annals of Oncology, 2003
exaly  

Characterization and mechanism insight of accelerated catalytic promiscuity of Sulfolobus tokodaii (ST0779) peptidase for aldol addition reaction

Applied Microbiology and Biotechnology, 2015
Rong Li, Hui Jian, Renjun Gao
exaly  

Acyl-peptide releasing enzyme from Sulfolobus tokodaii (ST0779) as a novel promiscuous biocatalyst for aldol addition

Catalysis Communications, 2015
Hui Jian, Renjun Gao, Mingdong Dong
exaly  

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Journal of Clinical Oncology, 2004
exaly  

CCI-779: a new targeted anticancer agent

Lancet Oncology, The, 2000
exaly  

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

Frontiers in Pharmacology
Alexandr Chernov
exaly